Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1641 1642 1644
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18462320 | METHOD OF TREATING AN ALLERGY WITH ALLERGEN-SPECIFIC MONOCLONAL ANTIBODIES | Non-Final OA | REGENERON PHARMACEUTICALS, INC. |
| 19258059 | VARIANT FC REGIONS | Non-Final OA | argenx BV |
| 17682314 | FORMULATION OF HIGHLY CONCENTRATED PHARMACOLOGICALLY ACTIVE ANTIBODY | Non-Final OA | Kashiv Biosciences, LLC |
| 17641297 | Treatment of Skin Blistering Diseases Using Antibodies | Non-Final OA | University of Cincinnati |
| 18141728 | MASKED SINGLE-DOMAIN ANTIBODIES AND METHODS THEREOF | Non-Final OA | Regents of the University of Minnesota |
| 16969425 | THERAPEUTIC FCRN-BASED BISPECIFIC MONOCLONAL ANTIBODIES | Non-Final OA | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. |
| 16640006 | INSULIN-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-1R) BINDING PROTEINS AND METHODS OF USE | Final Rejection | UNIVERSITY OF SOUTHERN CALIFORNIA |
| 18849006 | ANTIGEN-SPECIFIC THERAPY FOR AUTOIMMUNE DISEASES | Final Rejection | BODHI BIO LLC |
| 18644720 | METHODS AND COMPOSITIONS FOR MODIFYING MACROPHAGE POLARIZATION INTO PRO-INFLAMMATORY CELLS TO TREAT CANCER | Non-Final OA | OSE IMMUNOTHERAPEUTICS |
| 18106903 | TREATMENT OF AN ISCHEMIC HEART DISEASE | Final Rejection | Yeda Research and Development Co. Ltd. |
| 18257409 | CONJUGATED FUMONISIN TO PROTECT AGAINST MYCOTOXICOSIS | Non-Final OA | INTERVET INC. |
| 18516082 | Method for Primary Prevention of Allergic Disorders During Infancy Through IgE-Class-Specific Immunosuppression | Non-Final OA | Yutaka ISHIZAKA |
| 17771982 | ANTIBODIES FOR BINDING PLASMINOGEN | Non-Final OA | Monash University |
| 18301395 | Collagen Type XVI Assay | Non-Final OA | Nordic Bioscience A/S |
| 18256817 | HDAC6 BINDING PROTEINS AND THEIR ANTI-VIRAL USE | Non-Final OA | UNIVERSITY OF ZURICH |
| 18249886 | MULTISPECIFIC ANTIBODIES FOR TARGETING CD28 AND PD-L1 AND METHODS OF USE THEREOF | Non-Final OA | Janux Therapeutics, Inc. |
| 18023957 | ANTIBODY AGAINST CORONAVIRUS | Final Rejection | NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY |
| 18033942 | AN EX VIVO METHOD FOR REMOVAL OF TUMOR CELLS FROM INTRA-OPERATIVELY SALVAGED BLOOD | Non-Final OA | LINDIS BLOOD CARE GMBH |
| 18249187 | THERAPEUTIC CEMIP ANTIBODIES | Non-Final OA | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE |
| 17636425 | Anti-C7 Antibody Or Antibody Fragment | Non-Final OA | University College Cardiff Consultants Ltd |
| 17759384 | RELATED TARGET FOR TREATING FIBROTIC DISEASES AND APPLICATIONS THEREOF | Non-Final OA | Junling LIU |
| 17442791 | TREATING IMMUNE PLATELET DISORDERS USING ANTIGEN-BINDING FRAGMENTS | Non-Final OA | NSW Health Pathology |
| 17382821 | Anti-CD79 Antibodies and Their Uses | Final Rejection | Nepenthe Bioscience LLC |
| 17251695 | COMBINATION OF FACTOR VII AND AN ANTI-FACTOR IX/X BISPECIFIC ANTIBODY | Non-Final OA | Laboratoire Français du Fractionnnement et des Biotechnologies |
| 16876994 | RAPID TEST FOR CELLULAR FIBRONECTIN | Non-Final OA | PREDICTION BIOSCIENCES S.A.S. |
| 16244090 | ANTIBODY PROTAC CONJUGATES | Final Rejection | Development Center for Biotechnology |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy